Get the Stockscreener App
5.97
2.93%
-0.18
After Hours:
5.97
Design Therapeutics Inc stock is traded at $5.97, with a volume of 75,775.
It is down -2.93% in the last 24 hours and up +9.74% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
See More
Previous Close:
$6.15
Open:
$6.07
24h Volume:
75,775
Relative Volume:
0.33
Market Cap:
$343.12M
Revenue:
-
Net Income/Loss:
$-66.86M
P/E Ratio:
-4.4552
EPS:
-1.34
Net Cash Flow:
$-58.82M
1W Performance:
+8.94%
1M Performance:
+9.74%
6M Performance:
+36.93%
1Y Performance:
+172.60%
1-Day Range:
$5.87
$6.25
1-Week Range:
$5.43
$6.25
52-Week Range:
$2.13
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
5.97 | 343.12M | 0 | -66.86M | -58.82M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality - Business Wire
Rakovina Therapeutics to present AI-driven brain cancer research at Neuro-Oncology Conference - Proactive Investors USA
(DSGN) Technical Data - Stock Traders Daily
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences - The Manila Times
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work - The Manila Times
Design Therapeutics (DSGN) to Present at Two Major Healthcare Conferences | DSGN Stock News - StockTitan
Design Therapeutics stock soars to 52-week high of $6.91 By Investing.com - Investing.com Canada
Design Therapeutics stock soars to 52-week high of $6.91 - Investing.com India
Design Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Split-design approach enhances the therapeutic efficacy of ligand-based CAR-T cells against multiple B-cell malignancies - Nature.com
PTC data hot as Larimar, others advance in Friedreich’s ataxia - BioWorld Online
Long Term Trading Analysis for (DSGN) - Stock Traders Daily
Design Therapeutics Reports Strong Q3 and Pipeline Progress - TipRanks
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio - Marketscreener.com
Design Therapeutics Reports $254M Cash Runway, Advances Clinical Pipeline Through 2029 | DSGN Stock News - StockTitan
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - The Malaysian Reserve
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely - Yahoo Finance
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, - GlobeNewswire
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI - Yahoo Finance
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - PR Newswire
A new biotech, built around protein design, springs from David Baker’s lab - BioPharma Dive
Dr. Beyza Bulutoglu Celebrated for Dedication to the Field of Protein Engineering and Drug Discovery - 24-7 Press Release
At-home wearable-based monitoring predicts clinical measures and biological biomarkers of disease severity in Friedreich’s Ataxia | Communications Medicine - Nature.com
Spinocerebellar Ataxias Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
Seaport Therapeutics Secures $225M for New Kind of Depression Drug - MedCity News
Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological Diseases - BioSpace
Nitric Oxide-Photodelivering Materials with Multiple Functionalities: From Rational Design to Therapeutic Applications - ACS Publications
Synthetic Nanoassemblies for Regulating Organelles: From Molecular Design to Precision Therapeutics - ACS Publications
Spinocerebellar Ataxias Pipeline Review 2024: Clinical Trials Update and Key Companies Involved by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc - Barchart
Enhancing De Novo Drug Design across Multiple Therapeutic Targets with CVAE Generative Models - ACS Publications
When (DSGN) Moves Investors should Listen - Stock Traders Daily
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index - Yahoo Finance
OSE Immunotherapeutics Presents New “Cis-Demasking” - GlobeNewswire
ElevateBio Announces Advancements of its Proprietary Lipid Nanoparticle (LNP) Delivery Platform with Liver Targeting and De-Targeting Potential - ForexTV.com
Glycomic Therapeutics Market Innovations, Challenges, - openPR
Dimensional Fund Advisors LP Has $271,000 Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Marshall Wace LLP Buys New Shares in Security National Financial Co. (NASDAQ:SNFCA) - Defense World
Marshall Wace LLP Cuts Stock Holdings in ARC Document Solutions, Inc. (NYSE:ARC) - Defense World
Marshall Wace LLP Invests $81,000 in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Marshall Wace LLP Reduces Holdings in TrueCar, Inc. (NASDAQ:TRUE) - Defense World
Squarepoint Ops LLC Has $294,000 Stock Holdings in Civeo Co. (NYSE:CVEO) - Defense World
Squarepoint Ops LLC Increases Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Squarepoint Ops LLC Lowers Stock Holdings in AerSale Co. (NASDAQ:ASLE) - Defense World
Cyrus Biotechnology Congratulates David Baker, 2024 Nobel Laureate in Chemistry and Cyrus Co-Founder - BioSpace
Tech News | American Press Technology News - Business Wire
Windtree Therapeutics Publishes SEISMiC Phase 2b Trial Design for Cardiac Treatment - MyChesCo
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design - Yahoo Finance
Cubist Systematic Strategies LLC Grows Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Relay Therapeutics to Lay Off 10% of Workforce - BioSpace
Point72 Asset Management L.P. Buys 397,285 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):